Related News

Longevity expert shares the healthiest diet formula for long life

Image credits: Getty Images Aging does you less good and more harm. Unless you focus on healthy aging with beneficial diets and exercising, then you could age healthily and happily

Astronomers discover high-altitude clouds darkening skies in the YSES-1 system |

Astronomers observe thick slab clouds in the YSES-1 system, darkening the planet’s skies. These clouds are primarily mineral dust, probably containing iron. When the clouds break, iron could rain down.

5 ways to handle temper tantrums in teenagers

Try to notice what causes your teen’s tantrums. It could be feeling unheard, being denied something they want, or stress from school or friends. Once you identify these triggers, you

5 health issues that can occur due to Vitamin D deficiency

Vitamin D helps the body absorb calcium and phosphorus, which are important to build strong bones. Without enough vitamin D, your body cannot absorb these minerals properly. This can lead

Optical illusion: Think you have sharp eyesight? Spot the frog in this picture in under 5 seconds!

Optical illusions get our brain to exercise, and can be the perfect test of our observational skills and keen eye. An optical illusion is a visual phenomenon where the brain

Anne Wojcicki to buy back 23andMe and its data for $305 million

Word Count: 319 | Estimated Reading Time: 2 minutes

23andMe Founder and Board Member Anne Wojcicki speaks during a House Committee on Oversight and Government Reform hearing on June 10, 2025 in Washington, DC.

Andrew Harnik | Getty Images

Anne Wojcicki, the co-founder and former CEO of 23andMe, has regained control over the embattled genetic testing company after her new nonprofit, TTAM Research Institute, out bid Regeneron Pharmaceuticals, the company announced on Friday.

TTAM will acquire substantially all of 23andMe’s assets for $305 million, including its Personal Genome Service and Research Services business lines as well as telehealth subsidiary Lemonaid Health. It’s a big win for Wojcicki, who stepped down from her role as CEO when 23andMe filed for for Chapter 11 bankruptcy protection in March.

Last month, Regeneron announced that it would purchase most of 23andMe’s assets for $256 million after it came out on top during a bankruptcy auction. But Wojcicki submitted a separate $305 million bid through TTAM and pushed to reopen the auction. TTAM is an acronym for the first letters of 23andMe, according to the Wall Street Journal.

“I am thrilled that TTAM Research Institute will be able to continue the mission of 23andMe to help people access, understand and benefit from the human genome,” Wojcicki said in a statement.

23andMe gained popularity because of its at-home DNA testing kits that gave customers insight into their family histories and genetic profiles. The five-time CNBC Disruptor 50 company went public in 2021 via a merger with a special purpose acquisition company. At its peak, 23andMe was valued at around $6 billion.

The company struggled to generate recurring revenue and stand up viable research and therapeutics businesses after going public, and it’s been plagued by privacy concerns since hackers accessed the information of nearly 7 million customers in 2023.

TTAM’s acquisition is still subject to approval by the U.S. Bankruptcy Court for the Eastern District of Missouri.

WATCH: Regeneron CEO on 23andMe bid: Trying to balance individual privacy with biotech & genetics research